K-RAS Competitive Landscape Intensity
KRAS has been a constant hot topic for conversation for the past two years. An area where giants like Mirati and Amgen haven’t stopped to focus and perform, and now things have started to get […]
How Cracking KRAS with Mirati’s MRTX849, tougher than cracking Covid19?
Last October Mirati Therapeutics announced the first clinical results of the phase I / II study on MRTX849 in patients with solid tumors expressing KRAS G12C mutations. According to Mirati, MRTX849 has demonstrated clinical activity, […]